- Home
- Companies
- north america
- in vivo model
Show results for
Refine by
In Vivo Model Suppliers In North America
15 companies found
based inAustin, TEXAS (USA)
vivoVerse, Inc., formerly operating as Newormics LLC, develops and manufactures advanced microfluidics, automation, and AI/ML technologies to rapidly and ethically test toxicology/safety profiles of chemicals using C. elegans as a New Approach ...
C. elegans is recognized as a useful alternative in vivo model. The vivoChip® enables the use of C. elegans for high-content, multi-parametric analysis of neurodegeneration phenotypes from high-resolution ...
based inSan Diego, CALIFORNIA (USA)
Everyone at AnaBios shares a passion and commitment to make a difference in the development of promising new therapies and cures for patients by reducing the time and expense needed to bring these medicines to patients. We do this by generating ...
based inAudubon, PENNSYLVANIA (USA)
Globus Medical is a leading medical device manufacturer with the goal of improving the quality of life for patients with musculoskeletal disorders. We are inspired by the needs of these patients and by the surgeons and healthcare providers who treat ...
based inBillerica, MASSACHUSETTS (USA)
Access Vascular is offering a suite of vascular access devices that use our novel, patented biomaterial featuring MIMIX™ technology which is designed to prevent the most common and costly complications in vascular access. Keep treatment moving ...
based inIthaca, NEW YORK (USA)
iFyber is a preclinical contract research organization that offers custom research and development services to companies that operate at the interface of chemistry, biology, and materials science. iFyber is unique - we provide clients direct access ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the adenosine and TGF-β pathways, two major immunosuppressive mechanisms in the tumor microenvironment (TME). Solid tumors frequently express ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Aprotinin is a bovine pancreatic trypsin inhibitor (BPTI) inhibitor which inhibits trypsin and chymotrypsin with Kis of 0.06 pM and 9 nM, ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Acuitas is a private company based in Vancouver, British Columbia and was founded in February 2009. We are partnered with multiple pharmaceutical companies, biotechnology companies and academic institutes to advance nucleic acid therapeutics to the ...
Acuitas specializes in the development of lipid nanoparticle delivery systems for molecular therapeutics. Our scientists have synthesized over 500 novel cationic lipids which have been evaluated in in vivo ...
based inToronto, ONTARIO (CANADA)
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in people with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type ...
Zucara Therapeutics is developing ZT-01, a first-in-class, once-daily therapeutic to prevent insulin-induced hypoglycemia in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon ...
based inLa Tronche, FRANCE
INOVOTION is a Contract Research Laboratory implementing a unique approach to in vivo evaluation for anticancer drug discovery. Our cutting-edge proprietary technology provides early analysis of your compounds before the classical preclinical stage. ...
INOVOTION has developed a unique, highly sensitive and reproducible assay. It is applicable to all preclinical oncology and immuno-oncology drug discovery programs, and monitors the growth and metastatic dissemination of human tumor ...
based inCarlsbad, CALIFORNIA (USA)
Qualigen is a biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack diagnostic platform. The FastPack line of FDA-cleared and ...
based inSeattle, WASHINGTON (USA)
Nexelis is your partner for assay and biomarker development, advanced bioanalytical and laboratory testing, and translational immunology. As the leading specialty laboratory, we have unrivaled expertise in immunology, specifically in the areas of ...
Custom In Vivo Models and Testing Solutions. Selecting the appropriate in vivo model for your assays is critical for the success of your preclinical research program. At Nexelis, a ...
based inSchlieren, SWITZERLAND
InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Our robust and highly physiologically relevant suite of ...
An in vitro PDX model with in vivo-like heterogeneity. 3D InSight™ Tumor Microtissues from Patient-Derived Xenografts (PDX) are custom assay-ready 3D in vitro tumor models engineered to ...
based inEugene, OREGON (USA)
InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug development efforts. An expert in CRISPR genome ...
Extrachromosomal arrays enable your desired construct to be expressed without being integrated into the genome. Using extrachromosomal arrays, you can choose to express a variety of configurations of transgenes, such as ...
based inWhite Plains, NEW YORK (USA)
Oligomerix is a biotechnology company focused on developing disease-modifying and treatment therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy ...